质子放疗治疗的儿童脑肿瘤患者的放射性脑微出血
回顾性分析100例接受质子束放疗的儿童原发性脑肿瘤患者,随访中位57个月,脑微出血累积发生率在3年时达80%,87%的微出血位于受照≥30 Gy的脑区;最大放疗剂量、受照≥30 Gy脑组织百分比和体积以及质子放疗时年龄较小是显著危险因素,化疗不是显著危险因素。
要点
- 质子放疗后中位8个月出现脑微出血,3年累积发生率达80%。
- 87%的脑微出血位于受照≥30 Gy的脑区。
- 年轻年龄、高最大剂量及≥30 Gy受照脑百分比和体积是显著危险因素。
核心结论
- 质子放疗后数年内较高比例的儿童脑肿瘤患者出现脑微出血。
- 显著危险因素包括质子放疗时年龄较小、最大放疗剂量较高、受照≥30 Gy脑组织百分比和体积较高。
- 这些发现与光子放疗儿童脑肿瘤患者脑微出血情况相似。
- 无脑微出血需要手术干预。
研究设计与样本
- 回顾性研究,纳入100例接受质子束放疗的儿童原发性脑肿瘤患者。
- 通过系列磁共振成像(含磁敏感加权成像)诊断脑微出血,分析放疗计划确定各脑微出血剂量,使用临床记录确定危险因素。
主要发现
- 质子放疗时平均年龄8.1岁,中位随访57个月。
- 脑微出血中位出现时间8个月(均值11个月,范围3-28个月)。
- 质子放疗结束后1年、2年、3年、4年、5年和>5年脑微出血患者百分比分别为43%、66%、80%、81%、83%和81%。
- 87%的脑微出血位于受照≥30 Gy的脑区。
- 危险因素包括最大放疗剂量(P = .001)、受照≥30 Gy脑组织百分比(P = .0004)和体积(P = .0005)、质子放疗时年龄(P = .0004);化疗不是显著危险因素(P = .35)。
关键数值与推荐
- 脑微出血诊断依据系列磁共振成像包括磁敏感加权成像检查。
- 脑微出血中位出现时间8个月(均值11个月,范围3-28个月)。
- 87%的脑微出血位于受照≥30 Gy的脑区。
- 最大放疗剂量P = .001、受照≥30 Gy脑组织百分比P = .0004、体积P = .0005、质子放疗时年龄P = .0004为显著危险因素。
- 化疗P = .35不是显著危险因素。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Proton beam radiation therapy (PBT) has been increasingly used to treat pediatric brain tumors; however, limited information exists regarding radiation-induced cerebral microbleeds (CMBs) among these patients. The purpose of this study was to evaluate the incidence, risk factors, and imaging appearance of CMBs in pediatric patients with brain tumors treated with PBT. MATERIALS AND METHODS: A retrospective study was performed of 100 pediatric patients with primary brain tumors treated with PBT. CMBs were diagnosed by examination of serial magnetic resonance imaging scans, including susceptibility-weighted imaging. Radiation therapy plans were analyzed to determine doses to individual CMBs. Clinical records were used to determine risk factors associated with the development of CMBs in these patients. RESULTS: The mean age at time of PBT was 8.1 years. The median follow-up duration was 57 months. The median time to development of CMBs was 8 months (mean, 11 months; range, 3-28 months). The percentage of patients with CMBs was 43%, 66%, 80%, 81%, 83%, and 81% at 1 year, 2 years, 3 years, 4 years, 5 years, and >5 years from completion of proton radiation therapy. Most of the CMBs (87%) were found in areas of brain exposed to ≥30 Gy. Risk factors included maximum radiation therapy dose (P = .001), percentage and volume of brain exposed to ≥30 Gy (P = .0004, P = .0005), and patient age at time of PBT (P = .0004). Chemotherapy was not a significant risk factor (P = .35). No CMBs required surgical intervention. CONCLUSIONS: CMBs develop in a high percentage of pediatric patients with brain tumors treated with proton radiation therapy within the first few years after treatment. Significant risk factors for development of CMBs include younger age at time of PBT, higher maximum radiation therapy dose, and higher percentage and volume of brain exposed to ≥30 Gy. These findings demonstrate similarities with CMBs that develop in pediatric patients with brain tumor treated with photon radiation therapy.
引用
- Kralik SF, Mereniuk TR, Grignon L, et al. Radiation-Induced Cerebral Microbleeds in Pediatric Patients With Brain Tumors Treated With Proton Radiation Therapy. Int J Radiat Oncol Biol Phys. 2018. PMID: 30092336. doi:10.1016/j.ijrobp.2018.07.2016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。